Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
BioCryst ( (BCRX) ) has issued an update.
BioCryst Pharmaceuticals announced preliminary financial results for 2024, revealing strong revenue growth driven by its product ORLADEYO®, which saw a 34% year-over-year increase to $437 million. The company expects to continue this momentum into 2025, projecting ORLADEYO revenue between $515-$535 million and total revenue up to $560 million, while also advancing its clinical pipeline and aiming for profitability by the second half of 2025.
More about BioCryst
BioCryst Pharmaceuticals is a global biotechnology company focused on improving the lives of people with hereditary angioedema and other rare diseases. The company specializes in developing first-in-class or best-in-class oral small-molecule and protein therapeutics for difficult-to-treat diseases, with its flagship product being ORLADEYO®, the first oral, once-daily plasma kallikrein inhibitor.
YTD Price Performance: 2.81%
Average Trading Volume: 2,025,754
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.67B
Find detailed analytics on BCRX stock on TipRanks’ Stock Analysis page.
